GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 9f [PMID: 25782055] | RPX-7009 | RPX7009 | Vabomere (vaborbactam + meropenem)
vaborbactam is an approved drug (FDA (2017), EMA (2018))
Compound class:
Synthetic organic
Comment: Vaborbactam is a β-lactamase inhibitor [3]. Structurally it is based on a cyclic boronic acid pharmacophore.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| A combination of vaborbactam plus meropenem (Vabomere) is approved by the FDA as a treatment for serious urinary tract infections [2,4]. The same combination is authorised in the EU with the trade name Vaborem. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02168946 | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | Phase 3 Interventional | Melinta Therapeutics, Inc. | 1,6 | |
| NCT02166476 | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Phase 3 Interventional | Melinta Therapeutics, Inc. | 5 | |
External links ![]() |
|
For extended ADME data see the following: Drugs.com |